• If you are wondering whether UnitedHealth Group at around US$367 per share is offering fair value or a possible mispricing, it helps to break the story into what the stock has done recently and what the fundamentals suggest.
• Over the past month, the stock has returned 30.5%, even though the 1 year return sits at a 3.4% loss and the 3 year return at a 20.5% loss, while the year to date return is 9.2%.
• Recent coverage has focused on how investors are reassessing large healthcare stocks like UnitedHealth Group in light of sector wide regulatory discussions and shifts in sentiment toward managed care, which have put valuation and balance sheet strength in the spotlight. This broader context provides a backdrop for the recent 7 day return of a 0.9% decline compared with the strong 30 day move.
• On Simply Wall St's valuation checks, UnitedHealth Group currently scores 4 out of 6, and the next sections will walk through what that means across different valuation approaches, then finish with a way to think about value that goes beyond any single model.

Approach 1: UnitedHealth Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today using a required rate of return. The goal is to estimate what those future cash flows are worth in today’s dollars.

For UnitedHealth Group, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows available to shareholders. The latest twelve month free cash flow is about $19.3b. Analysts have provided explicit forecasts up to 2030, with Simply Wall St extrapolating beyond those years. The ten year projections in the model run from $20.7b in 2026 through to an estimated $41.3b in 2035, with each of these cash flows discounted back to today in the model.

Adding up all those discounted cash flows produces an estimated intrinsic value of around $885.45 per share. Compared with the recent share price of about $367, the DCF output implies the stock is 58.5% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests UnitedHealth Group is undervalued by 58.5%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: UnitedHealth Group Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. It ties directly to what the business is generating for shareholders today, so it is a useful cross check on more complex models like a DCF.

What counts as a “normal” P/E depends on how quickly earnings are expected to grow and how risky those earnings are perceived to be. Higher growth or lower perceived risk usually supports a higher P/E, while slower growth or higher perceived risk tends to justify a lower one.

UnitedHealth Group currently trades on a P/E of 27.7x, compared with the Healthcare industry average of 22.4x and a peer group average of 32.3x. Simply Wall St also calculates a “Fair Ratio” of 41.6x for UnitedHealth Group. This Fair Ratio is a proprietary estimate of what the P/E could be, based on factors such as earnings growth, profit margins, industry, market cap and risk profile, so it offers a more tailored reference point than a simple peer or industry comparison.

Since the current P/E of 27.7x is well below the Fair Ratio of 41.6x, this multiple-based view points to the stock trading below that model’s implied level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your UnitedHealth Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in as a simple way for you to attach a story to the numbers, connecting your view on UnitedHealth Group’s future revenue, earnings and margins to a forecast and then to a fair value that you can compare with the current share price.

On Simply Wall St’s Community page, Narratives let you pick or create a UnitedHealth Group story, link it to your own assumptions, and then see a fair value that updates automatically when new information such as earnings or news is added. This allows you to see where your view stands versus the latest data.

For example, some investors currently publish Narratives that imply higher fair values for UnitedHealth Group, such as around US$625 per share. Others use more cautious assumptions that point closer to about US$308 per share. By comparing these ranges with today’s market price, you can decide whether your own Narrative suggests the stock looks expensive, cheap or roughly in line with your expectations.

For UnitedHealth Group however we will make it really easy for you with previews of two leading UnitedHealth Group Narratives:

First is a bullish view that leans on analysts’ earnings and margin assumptions, and second is a more cautious view that focuses on execution, integration and regulatory risk. Both use the same stock, price and sector context you have just seen, but they tell very different stories about what that could mean for long term value.

Fair value in this bullish narrative: US$386.08 per share.

Implied pricing vs this fair value: around 4.9% undervalued at the recent price of US$367.28.

Revenue growth used in the narrative: 3.04% a year.

• Analysts in this narrative anchor on revenue of about US$492.0b and earnings of US$21.1b by 2029, with profit margins lifting from 2.7% to around 4.3%.
• The fair value relies on UnitedHealth Group trading on a P/E of about 20.5x in 2029, which is below the current P/E cited for the US Healthcare industry.
• Key risks in the story include Medicare mix and utilization, execution under the new CMS risk model, funding pressures and the potential impact of policy decisions on margins.

Fair value in this cautious narrative: US$308.35 per share.

Implied pricing vs this fair value: around 19.1% overvalued at the recent price of US$367.28.

Revenue growth used in the narrative: 4.23% a year.

• This narrative highlights UnitedHealth Group’s integrated Optum platform across insurance, care delivery, pharmacy benefits and analytics, and asks whether the current share price already reflects that positioning.
• It focuses on pressures from medical costs, regulation and scrutiny of vertical integration, and on the risk that valuation multiples could compress if growth or regulatory conditions turn less supportive.
• The author frames the stock as a mature, complex healthcare platform where execution, data usage and trust with regulators and providers are central to sustaining earnings quality.

Taken together, these Narratives give you a structured bullish and cautious case grounded in specific numbers for fair value, revenue growth and profitability, rather than just headlines or recent price moves. See what the community is saying about UnitedHealth Group.

Do you think there's more to the story for UnitedHealth Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.